JNJ-26489112

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H530003

CAS#: 871824-55-4

Description: JNJ-26489112 is a drug potentially for the treatment of depression and photosensitive epilepsy. Epilepsy studies have shown that single oral doses of JNJ-26489112 were well-tolerated and the pharmacodynamic effects appeared to be dose-related in patients with idiopathic, photosensitive epilepsy.

Chemical Structure

img
JNJ-26489112
CAS# 871824-55-4
Instruction

Theoretical Analysis

Hodoodo Cat#: H530003
Name: JNJ-26489112
CAS#: 871824-55-4
Chemical Formula: C9H11ClN2O4S
Exact Mass: 278.01
Molecular Weight: 278.710
Elemental Analysis: C, 38.79; H, 3.98; Cl, 12.72; N, 10.05; O, 22.96; S, 11.50

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: JNJ-26489112; JNJ26489112; JNJ 26489112

IUPAC/Chemical Name: Sulfamide, [[(2S)-6-chloro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-

InChi Key: KXSAIQPPGSSNKX-ZETCQYMHSA-N

InChi Code: InChI=1S/C9H11ClN2O4S/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12H,4-5H2,(H2,11,13,14)/t7-/m0/s1

SMILES Code: O=S(NC[C@@H]1OC2=CC=C(Cl)C=C2OC1)(N)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 278.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: McComsey DF, Smith-Swintosky VL, Parker MH, Brenneman DE, Malatynska E, White
HS, Klein BD, Wilcox KS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N,
Reitz AB, Maryanoff BE. Novel, broad-spectrum anticonvulsants containing a
sulfamide group: pharmacological properties of
(S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide
(JNJ-26489112). J Med Chem. 2013 Nov 27;56(22):9019-30. doi: 10.1021/jm400894u.
PubMed PMID: 24205976; PubMed Central PMCID: PMC4004761.

2: Di Prospero NA, Gambale JJ, Pandina G, Ford L, Girgis S, Moyer JA, Xi L, Nye
JS, Kasteleijn-Nolst Trenité D. Evaluation of JNJ-26489112 in patients with
photosensitive epilepsy: a placebo-controlled, exploratory study. Epilepsy Res.
2014 May;108(4):709-16. doi: 10.1016/j.eplepsyres.2014.01.018. PubMed PMID:
24560845.

3: Eichenbaum G, Zhou J, Kelley MF, Roosen W, Costa-Giomi P, Louden C, Di
Prospero NA, Pandina G, Singh JB, Ford L, Moyer JA, Nork TM, Ver Hoeve JN,
Aguirre GD. Implications of retinal effects observed in chronic toxicity studies
on the clinical development of a CNS-active drug candidate. Regul Toxicol
Pharmacol. 2014 Jul;69(2):187-200. doi: 10.1016/j.yrtph.2014.03.005. PubMed PMID:
24680767.

4: Zaccara G, Schmidt D. Do traditional anti-seizure drugs have a future? A
review of potential anti-seizure drugs in clinical development. Pharmacol Res.
2016 Feb;104:38-48. doi: 10.1016/j.phrs.2015.12.011. Review. PubMed PMID:
26689774.

5: Mariën D, Bailey GP, Eichenbaum G, De Jonghe S. Timing is everything for sperm
assessment in fertility studies. Reprod Toxicol. 2016 Sep;64:141-50. doi:
10.1016/j.reprotox.2016.05.001. PubMed PMID: 27181369.